5 Top-Ranked Stocks Driving ETF As S&P 500 Nears New Highs

Inside the SPY

The ETF holds 505 stocks in its basket with each accounting for no more than 6.5% of assets. This suggests a nice balance across each security and prevents heavy concentration. The fund is widely spread across sectors with information technology, healthcare, consumer discretionary, communication services and financials holding double-digit allocation each. It has AUM of $296.6 billion and charges 9 bps in fees per year. The product trades in heavy volume of around 72.4 million shares a day on average, ensuring higher liquidity with a tight bid/ask spread, leading to lower trading costs for investors.

SPY has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook. Though most stocks in the fund’s portfolio are in the green this year, we have highlighted five that are leading the way in the ETF and have a Zacks Rank #2, suggesting their continued outperformance.

Best-Performing Stocks of SPY

PayPal Holdings Inc. (PYPL - Free Report): It operates as a technology platform and digital payments company that enables digital and mobile payments on behalf of consumers and merchants worldwide. The stock has jumped 78.7% this year and has an estimated earnings growth of 18.7% for the year.

West Pharmaceutical Services Inc. (WST - Free Report): This global drug delivery technology company applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines, and consumer healthcare products. The stock has climbed 77.2% and has an estimated earnings growth of 31.8% for this year.

Rollins Inc. (ROL - Free Report): This company provides pest and termite control services to residential and commercial customers. It has gained 65.2% so far this year and has an estimated earnings growth rate of 6.8% for this year.

Regeneron Pharmaceuticals Inc. (REGN - Free Report): The biopharmaceutical company is focused on the discovery, development and commercialization of treatments targeting serious medical conditions. It has gained 62% so far this year and has an estimated earnings growth rate of 14.9%.

View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any specific ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.